Mom Incubators Limited · Class II · Cleared Aug 14, 2025
| K-number | K243437 |
| Device name | mOm Essential Incubator (ME1) |
| Applicant | Mom Incubators Limited |
| Product code | FMZ |
| Device class | Class II |
| Decision date | Aug 14, 2025 |
| Decision | Substantially Equivalent |
| Regulation | 880.5400 |
The mOm Essential Incubator (ME1) is a neonatal incubator that provides thermoregulation for premature and full-term infants up to 6 kg (13 lbs) in weight. It creates a heated, controlled environment with filtered air and is designed for use only in healthcare settings by trained personnel. The device can operate on AC power or an internal rechargeable battery.
The ME1 is a controller-based incubator with air temperature control only, unlike the predicate (Isolette 8000 plus) which offers both air and skin temperature modes plus optional oxygen and humidity control. The ME1 has a smaller physical footprint, lower weight (20 kg vs 98.5 kg), includes an internal battery for continued thermal care during power loss, and lacks some features like iris ports, serial/COM ports, and auxiliary power sockets. Temperature accuracy tolerance is ±1.5°C.
IEC 60601-1, IEC 60601-1-2, IEC 60601-1-6, IEC 60601-1-8, IEC 60601-2-19, ISO 10993 series (biocompatibility), ISO 18562 series (breathing gas pathways), IEC 62366 series (usability), and FDA guidance on software in medical devices.
Both devices share the same regulatory classification (Class II, 21 CFR 880.5400), intended use as neonatal incubators, and basic technology of temperature-controlled environments. The ME1's subset of features (air temperature only, no humidity/oxygen control, lower patient weight limit) targets a narrower population of healthier, near-term infants who do not require humidity control—a justified clinical distinction supported by WHO growth data. Performance testing demonstrates equivalent temperature control stability and safety margins. The technical differences reduce complexity without compromising core thermoregulation safety or effectiveness for the intended patient population.
View the full FDA submission: accessdata.fda.gov